论文部分内容阅读
应用高压液相法和光电子吸收法测定22例原发性肾病综合征治疗前患儿血中25一(oH)VitD_2浓度和桡骨中远端1/3处的骨密度(包括线密度和面密度),并对8例激素治疗后骨密度的复查结果如下:线密度(正常对照组0.3407士0.2972g/cm,治疗前0.2203士0.0809g/cm,治疗后0.1840士0.0372g/cm)治疗前、后与对照组比较P<0.05;面密度(对照组0.3287士0.1836g/cm~2,治疗前0.2666士0.0866g/cm~2,治疗后0.1895士0.0479g/cm~2)治疗前后较对照组明显下降(P<0.05);血25(OH)VitD_3对 照组40.1595士13.9239nmol/L,治疗前19.31士16.54nmol/L,P<0.01。上述结果表明:(1)患儿具有明显的骨代谢障碍,且其骨密度异常与血清血蛋白下降、尿蛋白排出增高及VitD_3下降同时存在,提示骨代谢紊乱与白蛋白、VitD3从尿中丢失,肠吸收钙障碍,致骨质稀疏相关。(2)结果证实激素对机体骨质代谢有肯定影响。在激素治疗中应常规应用VitD及钙荆以预防骨骼的发育异常。
High-pressure liquid and photoelectron absorption were used to measure the blood levels of 25-hydroxyvitamin D (2) and bone mineral density (including linear density and areal density) in the middle and distal 1/3 of 22 patients with primary nephrotic syndrome before treatment ), And 8 cases of hormone therapy after the review of bone mineral density results are as follows: linear density (normal control group 0.3407 disabilities 0.2972g / cm before treatment 0.2203 disabilities 0.0809g / cm, after treatment, 0.1840 disabilities 0.0372g / cm) before treatment, (P <0.05); the area density (0.3287 ± 0.1836g / cm ~ 2 in control group, 0.2666 ± 0.0866g / cm ~ 2 before treatment and 0.1895 ± 0.0479g / cm ~ 2 after treatment) (P <0.05); 40.1595 ± 13.9239nmol / L in serum 25 (OH) VitD_3 control group, 19.31 ± 16.54nmol / L before treatment, P <0.01. The above results show that: (1) children with significant bone metabolism disorders, and its abnormal bone mineral density decreased blood serum protein, increased urinary protein excretion and decreased VitD_3 exist, suggesting that disorders of bone metabolism and albumin, VitD3 loss from the urine , Intestinal absorption of calcium disorders, osteoporosis related. (2) the results confirmed that hormones have a positive effect on the body’s bone metabolism. In hormone therapy should be routinely used VitD and calcium Jing to prevent skeletal development abnormalities.